Emerging oral drug options for ulcerative colitis
This article aims to summarize the available evidence on oral drugs, which are now being explored in clinical trials or are ready to enter the clinics.AREAS COVERED: From 15 May to 11 June, we searched on PubMed using the keywords 'oral drugs ulcerative colitis,' 'ulcerative colitis clinical trials,' 'UC phase 2 and 3 trials' excluding case reports, case series, phase 1 and 4 studies, and studies about approved therapies.EXPERT OPINION: The findings discussed in this article suggest that the future treatment of UC patients will be probably characterized by the possibility of using various small-molecule drugs. All these ne...
Source: Expert Opinion on Emerging Drugs - September 5, 2023 Category: Drugs & Pharmacology Authors: Silvia Salvatori Benedetto Neri Irene Marafini Mattia Brigida Giovanni Monteleone Source Type: research
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma
Expert Opin Emerg Drugs. 2023 Aug 30:1-10. doi: 10.1080/14728214.2023.2250722. Online ahead of print.ABSTRACTINTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. Recent advances in immunotherapy such as chimeric antigen receptor T-cell therapy have significantly improved the outcomes in patients. Despite those advances, disease still recurs in many patients after multiple lines of therapy, and they eventually die. Many novel agents are under investigation. In this review, we focus on the synthetic drugs, usually small-molecule oral agents, that target a specific tumor-cell survival pa...
Source: Expert Opinion on Emerging Drugs - August 31, 2023 Category: Drugs & Pharmacology Authors: Ning Dong Lucia Perez-Lamas Julio C Chavez Source Type: research
Emerging drugs for dementia with Lewy Bodies: a review of Phase II & amp; III trials
Expert Opin Emerg Drugs. 2023 Aug 8:1-14. doi: 10.1080/14728214.2023.2244425. Online ahead of print.ABSTRACTINTRODUCTION: Despite faster cognitive decline and greater negative impact on patients and family caregivers, drug development efforts in Dementia with Lewy Bodies (DLB) fall behind those for Alzheimer's Disease (AD). Current off-label drug DLB treatment options are limited to symptomatic agents developed to address cognitive deficits in AD, motor deficits in Parkinson's Disease, or behavioral symptoms in psychiatric disease. Aided by recent improvements in DLB diagnosis, a new focus on the development of disease-mod...
Source: Expert Opinion on Emerging Drugs - August 2, 2023 Category: Drugs & Pharmacology Authors: Magdalena I Tolea Reem Ezzeddine Simone Camacho James E Galvin Source Type: research
